Ipsen and Exelixis’s treatment for liver cancer, Cabometyx, sees positive Phase III trial results

Ipsen’s collaboration with Exelixis is on track to file cancer treatment, Cabometyx, for a new liver cancer indication in the first half of next year, following positive Phase III trial results. The randomised, double-blind CELESTIAL study was set up to test Cabometyx in 760 patients who have advanced hepatocellular carcinoma (HCC), which is the sixth

Continue Reading